01
Low NADAC$1.10
→
Avg plan cost$1.57
Part D spend $41.9M
1× spread, current vs floor
Drug class profile · refreshed daily from federal data
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
2 molecules in this class, $55.5M combined CY2024 Part D spend across 196K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily
Class summary at a glance.
Every drug in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.
- Molecules in class
- 2tracked in Part D
- CY24 Part D spend
- $55.5Mcombined across class
- Total Rx claims
- 196K72K unique beneficiaries
- Generic mfrs (active)
- 16across all molecules
Every drug in this class, ranked by Part D spend.
02
Low NADAC$91.32
→
Avg plan cost$91.32
Part D spend $13.6M
1× spread, current vs floor